looksthread
Pharmaceutical
PharmaceuticalHair

Minoxidil

Also known as Rogaine, topical minoxidil, oral minoxidil

First-line for regrowth in androgenetic alopecia. Works on the growth phase rather than the hormonal cause, so it pairs naturally with a DHT blocker.

Evidence
Very strong
Typical cost
$15 – $60
Permanence
Ongoing use
Timeline
Shedding weeks 2–8. Visible regrowth at 4–6 months. Assess at 12 months.

Generic topical 5% roughly $15–40 for a three-month supply. Oral minoxidil is inexpensive but needs a prescription and monitoring.

How it works

A potassium channel opener and vasodilator. In hair it prolongs the anagen (growth) phase, shortens telogen, and enlarges miniaturised follicles. Topical minoxidil requires conversion by follicular sulfotransferase, which is why response varies so widely between people.

How it's used

Topical: 5% foam or solution, once or twice daily to a dry scalp, left for four hours minimum. Low-dose oral minoxidil is increasingly prescribed off-label by dermatologists and requires medical supervision for cardiovascular monitoring. Expect a shedding phase in weeks 2–8 — this is old hairs being pushed out by new growth, not failure.

Trade-offs

In favour

  • Genuinely regrows hair, not just retention
  • Available over the counter in topical form
  • Works anywhere on the scalp, including the crown
  • Non-hormonal, so no endocrine side effects

Against

  • Must be continued indefinitely — stopping reverses gains within months
  • Twice-daily application is a real adherence burden
  • Solution contains propylene glycol, a common irritant
  • Non-responders exist due to low sulfotransferase activity

Risks and side effects

Read before deciding
  • Initial shedding phase
  • Scalp irritation and contact dermatitis
  • Unwanted facial hair growth, more common with oral dosing
  • Oral minoxidil can cause fluid retention, tachycardia and lowered blood pressure — supervision required

How good is the evidence?

Very strong
Extensive high-quality evidence and guideline support.

Extensive randomised evidence for topical 5% in androgenetic alopecia. Low-dose oral use has rapidly growing but more recent evidence.

Sources

Sources point to guideline bodies and literature searches rather than single papers, so they stay accurate as the evidence moves.

More in Pharmaceutical